Jiangxi Fushine Pharmaceutical Co., Ltd. Class A

Jiangxi Fushine Pharmaceutical Co., Ltd. Class A

SSZSE:300497
13.20
CNY
+0.01
(+0.08%)
0.74EPS
23.41P/E
9.62BMarket Cap
May 03Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.42
1.64
1.87
1.84
2.28
2.73
3.14
3.27
2.63
3.03
2.97
2.21
2.15
3.65
Basic EPS, GAAP
0.14
0.17
0.3
0.42
0.42
0.46
0.71
0.7
0.09
-0.26
-0.37
-0.51
-0.1
0.76
Free Cash Flow per Basic Share
-0.06
-0.07
- -
0.26
0.27
0.03
0.03
-0.15
-1.12
-1.07
-0.57
0.09
-0.29
- -
Dividend per Share
0.03
0.03
0.11
0.11
0.17
0.19
0.18
0.18
0.26
0.1
0.1
0.1
0.1
0.15
Book Value per Share
0.74
0.91
1.44
1.76
2.17
2.6
3.41
6.39
5.24
4.87
4.52
3.96
4.05
4.76
Tangible Book Value per Share
0.53
0.71
1.29
1.56
1.91
2.36
3.14
5.86
4.77
4.42
4.08
3.54
3.52
4.21
Basic Weighted Avg Shares
313
311
310
415
421
427
431
456
543
544
543
534
550
538
Sales/Revenue/Turnover
443
511
580
764
958
1,163
1,354
1,493
1,430
1,647
1,610
1,178
1,185
1,966
Operating Margin (%)
13.19
13.66
20.95
24.21
22.08
21.96
30.27
29.03
14.43
2.29
-8.2
-7.56
0.72
27.3
Depreciation Expense
17
23
29
34
45
53
67
74
99
124
159
171
188
- -
Net Income, GAAP
45
53
94
174
178
195
306
319
49
-141
-201
-272
-55
411
Effective Tax Rate (%)
14.84
15.98
16.12
15.28
13.22
15.29
14.36
14.95
28.2
- -
- -
- -
- -
8.16
Profit Margin (%)
10.18
10.46
16.15
22.77
18.53
16.74
22.59
21.39
3.42
-8.59
-12.47
-23.1
-4.64
20.89
Working Capital
25
27
326
355
330
287
665
1,482
952
970
592
137
192
701
LT Debt
46
26
65
- -
93
37
294
65
353
1,043
998
736
809
717
Total Equity
230
283
596
784
967
1,153
1,528
3,048
2,911
2,690
2,471
2,177
2,200
2,584
Return on Invested Capital (%)
12.49
12.73
14.59
17.43
14.24
12.05
15.41
11.39
1.1
- -
- -
- -
- -
10.09
Return on Capital (%)
16.08
15.28
16.27
19.97
16.16
13.47
16.41
11.77
2.05
- -
- -
- -
- -
11.8
Return on Common Equity (%)
21.76
20.83
21.29
25.72
20.98
18.91
23.41
14.2
1.66
-5.09
-7.77
-11.66
-2.52
17.33

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
801
785
750
LT Borrowings
815
800
717
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
539
539
539
Market Capitalization
9,776
11,936
9,620

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,549
1,747
2,057
Cash, Cash Equivalents & STI
472
492
537
Accounts Receivable, Net
417
557
717
Inventories
382
394
408
Total Current Liabilities
1,270
1,363
1,356
Payables & Accruals
- -
- -
- -
ST Debt
801
785
750
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.5%
-6.21%
1.07%
Free Cash Flow
3,997.99%
37.59%
-453.46%
Net Income, GAAP
-31.77%
-95.35%
-79.78%
Sales/Revenue/Turnover
8.77%
-3.5%
0.61%
Total Cash Common Dividend
11.92%
1.91%
-1.33%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
340
342
294
201
1,178
2025
234
281
- -
416
1,185
2026
358
530
662
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
-0.04
-0.07
-0.39
-0.51
2025
- -
-0.02
- -
0.01
-0.1
2026
0.11
0.21
0.42
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
0.02
0.03
0.02
0.1
2025
0.03
0.02
- -
0.03
0.1
2026
0.03
0.02
0.07
- -
- -

Company Description

CEO
Jizu John Cheng
Full Time Employees
1,663
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 2, Yuli Industrial Zone Jingdezhen JX China 333000
IPO Date
Dec 22, 2015
Website
fushine.cn
Business
Jiangxi Fushine Pharmaceutical Co., Ltd. is a specialized enterprise engaged in the comprehensive research, development, manufacturing, and global distribution of active pharmaceutical ingredients and key pharmaceutical intermediates. The company is a prominent force in the production of anti-infective drug raw materials, notably offering a broad portfolio of β-lactamase inhibitors and carbapenem series antibiotics, with an established integrated value chain from initial components to finished APIs. Beyond its core pharmaceutical offerings, which also include antiviral drug intermediates and select finished formulations like argatroban injection and doxycycline hydrochloride dispersible tablets, Jiangxi Fushine has strategically diversified into advanced materials. This includes being a significant supplier of lithium-ion battery electrolyte additives such as vinylene carbonate (VC), and exploring the synthetic biology sector with microbial protein and other bio-fermentation products. Established in 2002 and headquartered in Jingdezhen, China, the company actively serves both domestic and international markets, exporting its diverse range of products to over twenty countries. Jiangxi Fushine Pharmaceutical was formerly known as Jingdezhen Fuxiang Pharmaceutical Co., Ltd. until its name change in August 2012. The company maintains a strong commitment to innovation, quality management, and has successfully passed multiple international inspections, including recent US FDA on-site audits.